Abstract
Nodal infiltration has been one of the most important prognostic factors in breast cancer. In recent decades, risk stratification has greatly changed, and is applied in accordance with hormone receptor and human epidermal growth factor receptor 2 (HER2) status. We compared the prognostic power of tumor subtype to nodal involvement in early breast cancer. We reviewed the medical records of 505 patients who had curative surgery for stage I or II breast cancer. We analyzed clinicopathologic factors according to tumor subtype and nodal involvement. Tumors were classified into 4 subtypes according to immunohistochemical status of estrogen receptor, progesterone receptor, HER2, and Ki67 labeling index. Disease-free survival (DFS) and overall survival were analyzed. There were 363 node-negative patients (71.9%) and 142 node-positive patients (28.1%). Luminal A, Luminal B, HER2, and triple-negative breast cancer subtypes were composed of 207 (41.0%), 147 (29.1%), 42 (8.3%), and 109 patients (21.6%), respectively. The median follow-up period was 89.5 months. Node negative-luminal A subtype showed the best prognosis with regard to 5-year DFS, and the pN1-triple negative subtype was associated with the shortest DFS (95.1% vs. 67.8%; hazar...Continue Reading
References
Aug 30, 2000·Nature·C M PerouD Botstein
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Jun 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Therese SorlieDavid Botstein
Oct 3, 2008·Breast Cancer Research and Treatment·James J DignamNorman Wolmark
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen ChiaKaren Gelmon
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Judith HughCharles Vogel
Dec 4, 2009·Breast Cancer Research and Treatment·Yeon Hee ParkYoung-Hyuck Im
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
May 12, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco ColleoniBarry A Gusterson
Oct 12, 2010·The Oncologist·Surabhi AmarEdith A Perez
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Dec 3, 2010·The New England Journal of Medicine·Miguel MartínUNKNOWN GEICAM 9805 Investigators
Dec 15, 2010·Molecular Oncology·Aleix Prat, Charles M Perou
Jul 1, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E MunzoneA Goldhirsch
Jan 25, 2012·Breast Cancer Research and Treatment·Jean-Philippe JacquinSilvy Laporte
Apr 21, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K GelmonS Verma
Oct 4, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H Joensuu, J Gligorov
Jun 7, 2013·Journal of the Korean Surgical Society·Jina ChangByung-In Moon
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Oct 24, 2013·Breast Cancer Research : BCR·Nuria RibellesEmilio Alba
Jan 2, 2014·Breast Cancer Research and Treatment·Andrea RoccaDino Amadori
May 16, 2014·World Journal of Clinical Oncology·Budhi Singh YadavSwaty Jhamb
May 28, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xia LiuYun Niu
Jun 4, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ines Vaz-LuisNancy U Lin
Jul 22, 2014·Cancer·Vandana G AbramsonJennifer A Pietenpol
Sep 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K GelmonS Verma